Skip to main content
. Author manuscript; available in PMC: 2021 Aug 21.
Published in final edited form as: Thromb Haemost. 2020 Sep 2;121(1):58–69. doi: 10.1055/s-0040-1715589

Fig. 4.

Fig. 4

Plasma-based coagulation assays in the accrued cohort. (A) Prothrombin time (PT) results in healthy (control) individuals and patients on each DOAC agent. (B) Activated partial thromboplastin time (aPTT) results in control and DOAC individuals. Riva – Tmax refers to rivaroxaban samples drawn at time of peak plasma rivaroxaban concentration (n = 25); Riva – All refers to cumulative values from all rivaroxaban samples drawn at peak and trough plasma drug levels (n = 49); Apixaban: n = 47; Dabigatran: n = 8. The horizontal line in panels (A) and (B) represents the normal reference range for PT and aPTT, respectively. (C) Steady-state plasma drug levels for each DOAC cohort. A small number of healthy (control) samples were randomly selected for anti-Xa activity testing. Each dot in panels (A)–(C) represents the mean of duplicate measurements for each individual sample. Box-and-whiskers diagrams extend from each quartile to the minimum/maximum distribution. (D) Sensitivity and specificity of PT and aPTT assays in the DOAC cohort. DOAC, direct oral anticoagulant.